Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Agilent Technologies (A) is a life sciences and diagnostics leader, while Stryker (SYK) dominates the medical technology and orthopedic implant space — two distinct healthcare sub-sectors with different growth drivers.
- Agilent's recent performance has been shaped by recovering demand in analytical instrumentation and easing headwinds in the biopharma spending cycle.
- Stryker continues to benefit from robust surgical procedure volumes, an aging global population, and strong MedSurg equipment demand.
- Both companies maintain solid balance sheets, but Stryker has historically commanded a higher valuation premium due to its recurring revenue mix and durable competitive moat.
- Sector rotation and interest rate expectations have influenced relative performance between the two stocks in recent market activity.
- Tickeron's AI-driven analysis evaluates both tickers through trend consistency, volatility metrics, and momentum indicators to identify which stock currently presents a more favorable setup.
Introduction
Healthcare is not a monolithic sector — it spans from cutting-edge laboratory instruments to life-changing surgical implants. Comparing A (Agilent Technologies) and SYK (Stryker Corporation) offers a window into two distinct investment approaches within the broader healthcare universe: one tied to pharmaceutical and diagnostic research spending, the other anchored in hospital capital equipment and surgical procedure demand. This comparison is particularly relevant for investors seeking to allocate capital across healthcare sub-industries with different sensitivity to macroeconomic cycles, regulatory environments, and demographic trends. Both are established leaders with global footprints, yet their return drivers diverge in meaningful ways worth understanding.
A Overview and Recent Performance
A — Agilent Technologies — is a global provider of analytical instruments, consumables, and services used across the life sciences, diagnostics, and applied chemical markets. The company's platforms support pharmaceutical R&D (research and development), clinical diagnostics, food safety testing, and environmental analysis, making it deeply embedded in the innovation pipeline of drug development and quality control.
In recent weeks, Agilent's stock has shown signs of stabilization after a period marked by cautious biopharma capital spending. Investor sentiment has gradually improved as commentary from management and industry peers has pointed to a bottoming in customer inventory destocking that weighed on instrument sales earlier in the cycle. Revenue diversification — spanning aftermarket consumables and service contracts — has provided a degree of resilience. Market participants have also noted Agilent's disciplined cost management and capital allocation, which have supported margins even as top-line growth faced pressure from restrained laboratory budgets. Relative to broader healthcare equipment peers, Agilent has traded at a more modest valuation multiple, reflecting both the cyclical exposure of its end markets and the market's wait-and-see posture toward a sustained demand recovery.
SYK Overview and Recent Performance
SYK — Stryker Corporation — is one of the world's largest medical technology companies, with leading positions in orthopedic implants, surgical robotics (notably the Mako system), neurotechnology, and hospital equipment such as beds, stretchers, and emergency room products. Stryker generates a substantial share of revenue from recurring, procedure-driven demand, which has historically provided greater visibility and stability compared to capital-equipment-focused peers.
Recent market activity has reflected continued confidence in Stryker's growth trajectory. Surgical procedure volumes have remained robust across key geographies, supported by aging demographics and expanded access to elective surgeries. The company's Mako robotic-assisted surgery platform continues to drive competitive differentiation and implant pull-through in joint replacement procedures. Margins have benefited from favorable product mix shifts and volume leverage, though macroeconomic factors — including foreign exchange headwinds and labor cost inflation in hospital settings — remain areas of analytical focus. Stryker's stock has generally commanded a premium valuation relative to the broader MedTech peer group, a reflection of the perceived durability of its business model and its track record of sustained mid-to-high single-digit revenue growth.
Trending AI Robots
For traders seeking an automated, data-driven edge, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered bots that collectively trade thousands of different tickers, each with distinct strategies, timeframes, and risk parameters. Only those bots demonstrating strong alignment with current market conditions — factoring in volatility regimes, sector momentum, and trend signals — are featured in this trending section. Users can explore bots with widely varied performance statistics: some have historically achieved win rates exceeding 70%, while others focus on capturing gains through swing trades lasting just a few days or positional strategies held over several weeks. Whether targeting short-term momentum or multi-week trend-following, the platform's diversity enables traders to discover strategies that match their personal risk tolerance and market outlook. Explore the Trending AI Robots today to see which automated strategies are currently navigating the market most effectively.
Head-to-Head Comparison
Agilent and Stryker operate in meaningfully different spheres of healthcare, and a head-to-head comparison reveals several key contrasts. Agilent's revenue is more sensitive to pharmaceutical and biotech R&D (research and development) budgets — capital spending decisions made by laboratory managers and research institutions — while Stryker's top line is driven largely by surgical procedure counts, which are influenced by hospital capacity, surgeon availability, and demographic tailwinds. This makes Agilent more cyclically exposed to R&D investment cycles, while Stryker benefits from relatively inelastic demand for joint replacements, trauma surgeries, and essential hospital equipment.
On valuation, Stryker has traditionally traded at a higher price-to-earnings multiple — a premium the market has awarded for its recurring revenue characteristics and competitive moat around its surgical robotics ecosystem. Agilent, while a leader in its own right, trades at a more grounded multiple that reflects both the cyclicality of instrument purchasing and the recovery narrative still unfolding. From a growth perspective, Stryker's mid-to-high single-digit organic revenue expansion has been steadier over the past several quarters, whereas Agilent has navigated a more uneven path tied to normalization following pandemic-era demand spikes.
Risk factors also diverge: Agilent faces exposure to pharmaceutical consolidation and shifting R&D spending patterns, while Stryker must contend with pricing pressures from hospital cost-containment efforts and regulatory scrutiny around medical device reimbursement. Both stocks have reacted to the broader interest rate environment, though Stryker's premium valuation makes it somewhat more sensitive to shifts in rate expectations that alter the discount rate applied to its future cash flows.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and stability metrics, Tickeron's AI framework would likely tilt toward Stryker (SYK) in the current market environment. The core reasoning rests on Stryker's more consistent upward trend structure, the resilience of procedure-driven demand, and the recurring nature of its revenue base — all of which tend to score favorably in AI-driven models that prioritize trend reliability and reduced downside volatility. Agilent's recovery trajectory is promising but introduces greater variability in near-term signal confidence. That said, the AI's assessment is probabilistic: Agilent could re-emerge as the more attractive candidate if instrument demand accelerates and leading indicators in pharma spending turn decisively positive. For now, the weight of evidence leans toward Stryker's combination of steady growth, demographic support, and technological differentiation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and SYK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 3 bearish.
- SYK’s TA Score: 4 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.73% price change this week, while SYK (@Medical/Nursing Services) price change was +1.13% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.48%. For the same industry, the average monthly price growth was +8.99%, and the average quarterly price growth was +0.10%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.22%. For the same industry, the average monthly price growth was -4.17%, and the average quarterly price growth was -20.80%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+0.48% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-2.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | SYK | A / SYK | |
| Capitalization | 37.5B | 121B | 31% |
| EBITDA | 1.96B | 6.44B | 30% |
| Gain YTD | -1.773 | -10.014 | 18% |
| P/E Ratio | 26.68 | 36.41 | 73% |
| Revenue | 7.23B | 25.3B | 29% |
| Total Cash | 1.81B | N/A | - |
| Total Debt | 3.36B | 14.7B | 23% |
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 68 | |
SMR RATING 1..100 | 44 | 57 | |
PRICE GROWTH RATING 1..100 | 50 | 58 | |
P/E GROWTH RATING 1..100 | 53 | 81 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is in the same range as SYK (10) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (68) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that SYK’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as SYK (57) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (50) in the Biotechnology industry is in the same range as SYK (58) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's P/E Growth Rating (53) in the Biotechnology industry is in the same range as SYK (81) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 51% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 51% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 47% |
| Advances ODDS (%) | 13 days ago 60% | 7 days ago 56% |
| Declines ODDS (%) | 3 days ago 64% | 1 day ago 53% |
| BollingerBands ODDS (%) | 1 day ago 52% | 1 day ago 60% |
| Aroon ODDS (%) | N/A | 1 day ago 45% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.